Clinical efficacy of Ranibizumab for exudative age-related macular degeneration
10.3760/cma.j.issn.0254-9026.2019.04.018
- VernacularTitle:雷珠单抗加量治疗渗出型老年性黄斑变性患者的临床疗效观察
- Author:
Yingyi LU
1
;
Xiaobing YU
;
Tong CHEN
;
Hong DAI
Author Information
1. 北京医院眼科国家老年医学中心 100730
- Keywords:
Macular degeneration;
Pigment epithelial of eye;
Choroidal neovascularization
- From:
Chinese Journal of Geriatrics
2019;38(4):423-426
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate changes in subretinal fluid(SRF),intraretinal fluid(IRF) and visual acuity after treatment with anti-vascular endothelial growth factor(VEGF)drugs in patients with wet age-related macular degeneration(WAMD)combined with disseminated epithelial detachment (PED).Methods Thirty-one WAMD patients with PED were retrospectively analyzed.Imaging characteristics of retinal morphological changes and changes in visual acuity were analyzed by optical coherence tomography(OCT)before and after treatment with Ranibizumab(1 mg).Results Thirtyone patients were treated with regular doses 3 to 17 times.WAMD patients with persistent/recurrent SRF,IRF and PED were treated with Ranibizumab(1 mg)1 to 3 times.There was a significant difference in the mean central retinal thickness(CRT)before and after 1 month of treatment(498.5 ±242.9 μm vs.406.0±201.9 μm,t=6.025,P＜0.01).85.7％ of patients(24 cases)had a decrease in SRF,60％(9 cases)had a decrease in IRF and 67.7％ (10 patients)had a decrease in PED,and 19 patients(32.7％)had increased visual acuity assessed by the Early Treatment of Diabetic Retinopathy Study(ETDRS) chart (≥ 5 letters),and 36 patients (61.2 ％) had stable vision.Conclusions Intravitreal injection of 1 mg Ranibizumab for the treatment of WAMD patients with PED can improve or stabilize visual acuity and reduce SRF,IRF and PED.
